Lantheus Holdings Inc (LNTH)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $6.64B
Last updated: Nov 17, 2026 at 11:06 AM ET
Lantheus Holdings Inc (LNTH) Earnings: Report Dates and Results
Lantheus Holdings (LNTH) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Lantheus Holdings reported EPS of $1.43, above the $1.01 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LNTH has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 6.8% below the $1.46 reported for the quarter ended Dec 31, 2025.
LNTH Earnings Call
The latest LNTH earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 40 quarters below that had an estimate, LNTH beat 34, missed 4 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $389.91M, up 1.5% from $384.01M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.43 | $1.01 | N/A | +41.58% | Beat | +12.6% | 7 | 2 up, 1 down | Nov 5, 2026 | $389.91M |
| Jun 30, 2026 | $1.32 | $1.11 | N/A | +18.92% | Beat | -15.9% | 11 | 1 up, 1 down | Aug 6, 2026 | $388.18M |
| Mar 31, 2026 | $1.46 | $1.23 | $1.08 - $1.34 | +18.70% | Beat | -4.6% | 12 | 0 up, 1 down | May 7, 2026 | $377.33M |
| Dec 31, 2025 | $1.46 | $0.94 | $0.86 - $1.29 | +55.32% | Beat | -8.2% | 13 | 1 up, 0 down | Feb 26, 2026 | $406.79M |
| Sep 30, 2025 | $1.27 | $1.27 | $1.16 - $1.36 | 0.00% | In line | -25.3% | 13 | 1 up, 2 down | Nov 6, 2025 | $384.01M |
| Jun 30, 2025 | $1.57 | $1.68 | $1.57 - $2.04 | -6.55% | Miss | -12.8% | 13 | 1 up, 1 down | Aug 6, 2025 | $378.05M |
| Mar 31, 2025 | $1.53 | $1.65 | $1.55 - $1.73 | -7.27% | Miss | -9.5% | 13 | 1 up, 1 down | May 7, 2025 | $372.76M |
| Dec 31, 2024 | $1.59 | $1.54 | $1.44 - $1.72 | +3.04% | Beat | -9.1% | 13 | 0 up, 2 down | Feb 26, 2025 | $391.11M |
| Sep 30, 2024 | $1.70 | $1.56 | $1.45 - $1.74 | +8.97% | Beat | +15.6% | 11 | 0 up, 0 down | Nov 6, 2024 | $378.73M |
| Jun 30, 2024 | $1.80 | $1.83 | $1.81 - $1.85 | -1.64% | Miss | +16.9% | 11 | 1 up, 0 down | Jul 31, 2024 | $394.09M |
| Mar 31, 2024 | $1.69 | $1.54 | $1.52 - $1.62 | +9.74% | Beat | +15.0% | 10 | 0 up, 0 down | May 2, 2024 | $369.98M |
| Dec 31, 2023 | $1.75 | $1.45 | $1.35 - $1.59 | +20.69% | Beat | +27.7% | 10 | 2 up, 0 down | Feb 22, 2024 | $354.00M |
| Sep 30, 2023 | $1.47 | $1.32 | $1.26 - $1.35 | +11.36% | Beat | +48.5% | 9 | 0 up, 0 down | Nov 2, 2023 | $319.95M |
| Jun 30, 2023 | $1.54 | $1.31 | $1.28 - $1.37 | +17.56% | Beat | +73.0% | 8 | 0 up, 1 down | Aug 3, 2023 | $321.70M |
| Mar 31, 2023 | $1.47 | $1.29 | $1.03 - $1.30 | +13.95% | Beat | +51.5% | 8 | 1 up, 0 down | May 4, 2023 | $300.78M |
| Dec 31, 2022 | $1.37 | $0.96 | $0.89 - $1.01 | +42.71% | Beat | +448.0% | 7 | 2 up, 0 down | Feb 23, 2023 | $263.17M |
| Sep 30, 2022 | $0.99 | $0.83 | $0.75 - $0.86 | +19.28% | Beat | +1137.5% | 7 | 0 up, 0 down | Nov 3, 2022 | $239.29M |
| Jun 30, 2022 | $0.89 | $0.70 | $0.70 - $0.71 | +27.14% | Beat | +709.1% | 3 | 0 up, 0 down | Aug 4, 2022 | $223.72M |
| Mar 31, 2022 | $0.97 | $0.46 | $0.45 - $0.47 | +110.87% | Beat | +1840.0% | 4 | 0 up, 0 down | Apr 29, 2022 | $208.88M |
| Dec 31, 2021 | $0.25 | $0.17 | $0.16 - $0.17 | +47.06% | Beat | +257.1% | 3 | 0 up, 0 down | Feb 24, 2022 | $129.56M |
| Sep 30, 2021 | $0.08 | $0.06 | $0.06 - $0.07 | +33.33% | Beat | +100.0% | 3 | N/A | Nov 4, 2021 | $102.07M |
| Jun 30, 2021 | $0.11 | $0.05 | $0.04 - $0.06 | +120.00% | Beat | +10.0% | 4 | N/A | Jul 28, 2021 | $101.06M |
| Mar 31, 2021 | $0.05 | -$0.01 | -$0.02 - $0.00 | +600.00% | Beat | -86.1% | 4 | N/A | May 4, 2021 | $92.51M |
| Dec 31, 2020 | $0.07 | $0.01 | -$0.07 - $0.06 | +600.00% | Beat | -79.4% | 4 | N/A | Feb 25, 2021 | $94.15M |
| Sep 30, 2020 | $0.04 | -$0.06 | -$0.09 - $0.22 | +166.67% | Beat | -85.7% | 4 | N/A | Nov 5, 2020 | $88.54M |
| Jun 30, 2020 | $0.10 | $0.06 | $0.02 - $0.15 | +66.67% | Beat | -63.0% | 4 | N/A | Jul 30, 2020 | $66.01M |
| Mar 31, 2020 | $0.36 | $0.29 | N/A | +24.14% | Beat | +28.6% | 3 | N/A | Apr 30, 2020 | $90.70M |
| Dec 31, 2019 | $0.34 | $0.30 | $0.28 - $0.31 | +13.33% | Beat | +41.7% | 4 | N/A | Feb 25, 2020 | $89.35M |
| Sep 30, 2019 | $0.28 | $0.21 | $0.20 - $0.25 | +33.33% | Beat | +16.7% | 4 | N/A | Oct 31, 2019 | $85.78M |
| Jun 30, 2019 | $0.27 | $0.25 | N/A | +8.00% | Beat | +3.8% | 4 | N/A | Jul 25, 2019 | $85.70M |
| Mar 31, 2019 | $0.28 | $0.25 | $0.24 - $0.25 | +12.00% | Beat | +27.3% | 4 | N/A | Apr 30, 2019 | $86.51M |
| Dec 31, 2018 | $0.24 | $0.14 | $0.10 - $0.16 | +71.43% | Beat | +100.0% | 4 | N/A | Feb 19, 2019 | $86.27M |
| Sep 30, 2018 | $0.24 | $0.18 | $0.15 - $0.22 | +33.33% | Beat | 0.0% | 4 | N/A | Oct 30, 2018 | $88.90M |
| Jun 30, 2018 | $0.26 | $0.22 | $0.13 - $0.29 | +18.18% | Beat | -38.1% | 4 | N/A | Aug 1, 2018 | $85.57M |
| Mar 31, 2018 | $0.22 | $0.22 | $0.20 - $0.24 | 0.00% | In line | -21.4% | 3 | N/A | May 2, 2018 | $82.63M |
| Dec 31, 2017 | $0.12 | $0.20 | $0.11 - $0.28 | -40.00% | Miss | -33.3% | 4 | N/A | Feb 26, 2018 | $81.24M |
| Sep 30, 2017 | $0.24 | $0.20 | $0.19 - $0.23 | +20.00% | Beat | +60.0% | 4 | N/A | Nov 2, 2017 | $79.94M |
| Jun 30, 2017 | $0.42 | $0.23 | $0.22 - $0.26 | +82.61% | Beat | +75.0% | 4 | N/A | Aug 1, 2017 | $88.84M |
| Mar 31, 2017 | $0.28 | $0.19 | N/A | +47.37% | Beat | +86.7% | N/A | N/A | May 2, 2017 | $81.36M |
| Dec 31, 2016 | $0.18 | $0.13 | N/A | +38.46% | Beat | +38.5% | N/A | N/A | Feb 21, 2017 | $74.35M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $5.83, down 14.0% from the year before. It was $0.72 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $5.83 | -14.0% |
| Dec 31, 2024 | $6.78 | +8.8% |
| Dec 31, 2023 | $6.23 | +47.6% |
| Dec 31, 2022 | $4.22 | +761.2% |
| Dec 31, 2021 | $0.49 | -14.0% |
| Dec 31, 2020 | $0.57 | -51.3% |
| Dec 31, 2019 | $1.17 | +21.9% |
| Dec 31, 2018 | $0.96 | -9.4% |
| Dec 31, 2017 | $1.06 | +47.2% |
| Dec 31, 2016 | $0.72 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 6,300 words across 13 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 6,297 | 13 | |
| 2025Q4 | Dec 31, 2025 | 8,565 | 15 | |
| 2025Q3 | Sep 30, 2025 | 4,782 | 12 | |
| 2025Q2 | Jun 30, 2025 | 7,181 | 17 | |
| 2025Q1 | Mar 31, 2025 | 8,340 | 18 | |
| 2024Q4 | Dec 31, 2024 | 6,721 | 18 | |
| 2024Q3 | Sep 30, 2024 | 7,067 | 17 | |
| 2024Q2 | Jun 30, 2024 | 7,316 | 18 |
2026Q1 Earnings Call
Opening remarks
Mark Kinarney Vice President, Investor Relations Thank you. Good morning. With me today are Mary Heino, our CEO and Executive Chairperson; Amanda Morgan, our Chief Commercial Officer; and Bob Marshall, our CFO. We will begin with prepared remarks and then take your questions. This morning, we issued a press release, which was furnished to the SEC under Form 8-K reporting our first quarter 2026 results. The release and today's slide presentation are available on the Investors section of our website. Any comments could include forward-looking statements. Actual results may differ materially from these statements due to a variety of risks and uncertainties, which are detailed in our SEC filings. Discussions will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is included in the Investors section of our website. I will now turn the call over to Mary Heino.
Mary Heino CEO and Executive Chairperson Thank you, Mark, and good morning, everyone. We had a strong start to the year with solid performance across PYLARIFY, NEUROCEQ and DEFINITY. These results reflect our ongoing commitment to focus and discipline across the organization. As we said last quarter, 2026 is a year of commercial execution and regulatory milestones. We're making deliberate choices about where we focus our commercial efforts and deploying capital so we're positioned to deliver solid results in 2026 and accelerate growth in 2027. Our corporate focus is centered on radiodiagnostics and our priorities for 2026 are clear. First, maintain our market leadership in PSMA PET while preparing for a seamless transition to PYLARIFY TRUVU, our newly approved PSMA PET formulation beginning in the fourth quarter. Second, continue to build momentum for NEUROCEQ through deeper penetration within existing accounts, leveraging the breadth of the Lantheus portfolio to unlock incremental growth opportunities and expanding our manufacturing footprint, increasing supply availability. Third, advance our late-stage clinical portfolio through key regulatory milestones and ensure launch readiness aligned with coding, coverage, payment, customer preparedness and market opportunity. And finally, allocate capital with discipline, prioritizing radiodiagnostics while evaluating value-maximizing alternatives for our radiotherapeutic assets. In addition to effective commercial execution, we advanced several key programs during the quarter that support our long-term growth strategy. On March 6, the FDA approved PYLARIFY TRUVU, our new PSMA PET imaging agent. PYLARIFY TRUVU offers the same proven diagnostic properties as PYLARIFY with a similar safety and efficacy profile. The value add of this product will be the larger batch sizes that can be enabled at manufacturing sites with high energy cyclotrons. This creates the potential to serve more patients and support a broader geographic reach.
Frequently Asked Questions About LNTH
When is Lantheus Holdings's next earnings date?
Lantheus Holdings's next earnings report is expected for Feb 24, 2027.
Did LNTH beat earnings estimates last quarter?
Yes. Lantheus Holdings reported EPS of $1.43 for the quarter ended Sep 30, 2026, above the $1.01 estimate, a 41.58% surprise.
What EPS do analysts expect from LNTH next quarter?
The consensus EPS estimate for Lantheus Holdings for the quarter ending Dec 31, 2026 is $1.36 from 11 analysts, with estimates from $1.02 to $1.63.
How often does LNTH beat earnings estimates?
Lantheus Holdings beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +15.47%.
LNTH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts